120
Participants
Start Date
August 31, 2011
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
Two Multimeric-001 administrations followed by TIV
Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
One administration of Multimeric-001 followed by TIV
One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
One administration of adjuvanted M-001 followed by TIV
One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
One administration of placebo followed by TIV
One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
Hadassah medical center, Jerusalem
Lead Sponsor
BiondVax Pharmaceuticals ltd.
INDUSTRY